User account | Research To Practice
Research To Practice requires users to log in to view educational content. All content is available without
Related Articles
Molecular Testing Helps First-Line Treatment Landscape Evolve in Pancreatic Cancer
Tanios S. Bekaii-Saab, MD, discusses the evolution of frontline treatment in advanced pancreatic cancer.
Trump picks Stanford’s Jay Bhattacharya to lead NIH
Bhattacharya would be in charge of Trump’s bold goals to reform the NIH, which spends billions to fund medical research.
Truqap combination in PTEN-deficient metastatic hormone-sensitive prostate cancer demonstrated statistically significant and clinically meaningful improvement in radiographic progression-free survival in CAPItello-281 Phase III trial
Positive high-level results from the CAPItello-281 Phase III trial showed that AstraZeneca’s Truqap (capivasertib) in combination with abiraterone and androgen deprivation therapy (ADT) demonstrated a…
Decode LLM Evaluation: Benchmarks, Metrics, and Leaderboards
This comprehensive LLM evaluation guide explains the importance of benchmarks, metrics, and leaderboards to measure LLM capabilities in real world applications.
Impaired development of memory B cells and antibody responses in humans and mice deficient in PD-1 signaling
Ogishi, Kitaoka, et al. examine humans deficient in PD-1 and PD-L1 as well as associated mouse models and find that PD-1 and PD-L1 promote B cell…
Glucose limitation protects cancer cells from apoptosis induced by pyrimidine restriction and replication inhibition
Nature Metabolism – Nam et al. show that limited glucose availability similar to the tumour microenvironment confers resistance against chemotherapeutic drugs that target DNA synthesis.
New study tests levels of chemicals linked to cancer in Pittsburgh-area water
We’ll show you how forever chemicals get from our homes to the water system and what’s being done to protect you, tonight on Channel 11…
Roche’s TIGIT prospect fails another phase 3 lung cancer test
Roche’s SKYSCRAPER-01 has fallen down. | Roche’s SKYSCRAPER-01 has fallen down. The phase 3 trial found adding the TIGIT candidate tiragolumab to a checkpoint inhibitor…
